Jesus G Berdeja (Jesus Berdeja, Jesús G Berdeja)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 14

Top Topics

Histone Deacetylase

Acute Myeloid Leukemia

Multiple Myeloma

Top Venues

American journal of hematology

Leukemia & lymphoma

Nature medicine

Nature genetics

This page only lists publications with an associated author ORCID identifier.

Publications

Sosana Delimpasi, Meletios- Athanasios Dimopoulos, Jan Straub, Argiris Symeonidis, Luděk Pour, Roman Hájek, Cyrille Touzeau, Viralkumar K Bhanderi, Jesus G Berdeja, Petr Pavlíček, Jeffrey V Matous, Pawel J Robak, Kaveri Suryanarayan, Alison Miller, Miguel Villarreal, Dasha Cherepanov, Jaydeep K Srimani, Huilan Yao, Richard Labotka, Robert Z Orlowski
Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myeloma. American journal of hematology (2024)
Sikander Ailawadhi, Bertrand Arnulf, Krina K Patel, Michele Cavo, Ajay K Nooka, Salomon Manier, Natalie S Callander, Luciano José Megale Costa, Ravi Vij, Nizar J Bahlis, Philippe Moreau, Scott R Solomon, Ingerid Weum Abrahamsen, Rachid C Baz, Annemiek Broijl, Christine Chen, Sundar Jagannath, Noopur Raje, Christof Scheid, Michel Delforge, Reuben Benjamin, Thomas Pabst, Shinsuke Iida, Jesus G Berdeja, Sergio A Giralt, Anna Truppel-Hartmann, Yanping Chen, Xiaobo Zhong, Fan Wu, Julia Piasecki, Laurie Eliason, Devender S Dhanda, Jasper Felten, Andrea Caia, Mark Cook, Mihaela Popa-Mckiver, Paula Rodriguez Otero
Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. Blood (2024)
Sosana Delimpasi, Meletios- Athanasios Dimopoulos, Jan Straub, Argiris Symeonidis, Luděk Pour, Roman Hájek, Cyrille Touzeau, Viralkumar K Bhanderi, Jesus G Berdeja, Petr Pavlíček, Jeffrey V Matous, Pawel J Robak, Kaveri Suryanarayan, Alison Miller, Miguel Villarreal, Dasha Cherepanov, Jaydeep K Srimani, Huilan Yao, Richard Labotka, Robert Z Orlowski
Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myeloma. American journal of hematology 99 (9) (2024)
Sheri Skerget, Daniel Penaherrera, Ajai Chari, Sundar Jagannath, David S Siegel, Ravi Vij, Gregory Orloff, Andrzej Jakubowiak, Ruben Niesvizky, Darla K Liles, Jesus G Berdeja, Moshe Levy, Jeffrey Wolf, Saad Z Usmani, null null, Austin W Christofferson, Sara Nasser, Jessica L Aldrich, Christophe Legendre, Brooks A Benard, Chase Miller, Bryce Turner, Ahmet Kurdoglu, Megan Washington, Venkata D Yellapantula, Jonathan R Adkins, Lori Cuyugan, Martin Boateng, Adrienne Helland, Shari Kyman, Jackie McDonald, Rebecca Reiman, Kristi Stephenson, Erica Tassone, Alex Blanski, Brianne Livermore, Meghan Kirchhoff, Daniel C Rohrer, Mattia D'Agostino, Manuela Gamella, Kimberly Collison, Jennifer Stumph, Pam Kidd, Andrea Donnelly, Barbara Zaugg, Maureen Toone, Kyle McBride, Mary DeRome, Jennifer Rogers, David Craig, Winnie S Liang, Norma C Gutiérrez, Scott D Jewell, John Carpten, Kenneth C Anderson, Hearn Jay Cho, Daniel Auclair, Sagar Lonial, Jonathan J Keats
Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes. Nature genetics (2024)
Sudhir Manda, Bertrand M Anz, Christopher Benton, E Randolph Broun, Habte A Yimer, John S Renshaw, George Geils, Jesus G Berdeja, Jose Cruz, Jason M Melear, Suzanne Fanning, Luke Fletcher, Yukun Li, Yinghui Duan, Michael E Werner, Jalaja Potluri, Madhavi V Pai, William B Donnellan
A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia. Hematological oncology 42 (3) (2024)
Yi Lin, Noopur S Raje, Jesus G Berdeja, David S Siegel, Sundar Jagannath, Deepu Madduri, Michaela Liedtke, Jacalyn Rosenblatt, Marcela V Maus, Monica Massaro, Fabio Petrocca, Ashish Yeri, Olivia Finney, Andrea Caia, Zhihong Yang, Nathan Martin, Timothy B Campbell, Julie Rytlewski, Jaymes Fuller, Kristen Hege, Nikhil C Munshi, James N Kochenderfer
Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial. Nature medicine (2023)
Juan José Lahuerta, Irene Manrique, Julie A Rytlewski, Timothy Campbell, Christian C Kazanecki, Nathan Martin, Larry D Anderson, Jesus G Berdeja, Sagar Lonial, Noopur S Raje, Yi Lin, Phillipe Moreau, Jesús San F Miguel, Nikhil C Munshi, Shari Kaiser
Time-dependent prognostic value of serological and measurable residual disease assessments after idecabtagene vicleucel. Blood cancer discovery (2023)
Benjamin A Derman, Jeffrey A Zonder, Donna Reece, Craig E Cole, Jesus G Berdeja, Andrew T Stefka, Ajay Major, Mitul D Gandhi, Kent A Griffith, Jagoda Jasielec, Andrzej J Jakubowiak
Phase 1/2 study of carfilzomib, pomalidomide, dexamethasone with and without daratumumab in relapsed multiple myeloma. Blood advances (2023)
Thomas Martin, Saad Z Usmani, Jesus G Berdeja, Mounzer Agha, Adam David Cohen, Parameswaran N Hari, David Avigan, Abhinav Deol, Myo Htut, Alexander Lesokhin, Nikhil C Munshi, Elizabeth O'Donnell, A Keith Stewart, Jordan M Schecter, Jenna D Goldberg, Carolyn C Jackson, Tzu-Min Yeh, Arnob Banerjee, Alicia Allred, Enrique Zudaire, William Deraedt, Yunsi Olyslager, Changwei Zhou, Lida Pacaud, Deepu Madduri, Andrzej J Jakubowiak, Yi Lin, Sundar Jagannath
Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Michael Joseph Slade, Thomas G Martin, Nitya Nathwani, Mark A Fiala, Michael P Rettig, Feng Gao, Abhinav Deol, Francis K Buadi, Jonathan L Kaufman, Craig C Hofmeister, Tara K Gregory, Jesus G Berdeja, Ajai Chari, Ashley Rosko, Ravi Vij
Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma. Leukemia 36 (12) (2022)
Jesus D Gonzalez-Lugo, Suman Kambhampati, Abdulraheem Yacoub, William B Donnellan, Jesus G Berdeja, Prafulla Bhagat, Karen Fehn, Cassady Remy, Sakshi Jasra, Mohammed Kazemi, Kith Pradhan, Mimi Y Kim, Ioannis Mantzaris, R Alejandro Sica, Nishi Shah, Mendel Goldfinger, Noah Kornblum, Kira Gritsman, Ira Braunschweig, Ulrich Steidl, Britta Will, Aditi Shastri, Amit K Verma
Lenalidomide and Eltrombopag for Treatment of Low or Intermediate Risk Myelodysplastic Syndrome: Result of a Phase 2 Clinical Trial. Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Jesus G Berdeja, Tara K Gregory, Edward A Faber, Lowell L Hart, Joseph R Mace, Edward R Arrowsmith, Ian W Flinn, Jeffrey V Matous
A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose-expansion cohort. American journal of hematology 96 (4) (2021)
Melissa Alsina, Ola Landgren, Noopur Raje, Ruben Niesvizky, William I Bensinger, Jesus G Berdeja, Tibor Kovacsovics, David H Vesole, Belle Fang, Amy S Kimball, David S Siegel
A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma. American journal of hematology 96 (2) (2020)
Jesus G Berdeja, Michael C Heinrich, Shaker R Dakhil, Stuart L Goldberg, Martha Wadleigh, Philip Kuriakose, Jorge E Cortes, Jerald Radich, Bret Helton, David A Rizzieri, Carole Paley, Ilva Dautaj, Michael J Mauro
Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis. Leukemia & lymphoma 60 (10) (2019)